Gene therapy for subtype of retinitis pigmentosa granted orphan status

An RNA-based gene therapy made by Dutch biotech company ProQR Therapeutics has received Orphan Drug Designation from the FDA and European Medicines Agency for treatment of Usher syndrome type II, a form of retinitis pigmentosa.
[Read More …]
Source: Daily Dose of Eye Care

Please follow and like us:
RSS
Facebook
Facebook
Google+
Google+
https://www.lvcenter4sight.com/gene-therapy-for-subtype-of-retinitis-pigmentosa-granted-orphan-status/

© Copyright Lehigh Valley Center For Sight